Related Experiment Video
Updated: Jul 15, 2026
05:17
Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples
Published on: July 28, 2016
Age-related paraoxonase activity changes in Turkish population
Ercan Saruhan1, Abdullah Olgun, Kamile Oztürk
1Department of Biochemistry and Clinical Biochemistry, Gülhane School of Medicine, 06018 Etlik, Ankara, Turkey. sarerc@yahoo.com
Annals of the New York Academy of Sciences
|April 27, 2007
Summary
Paraoxonase1 (PON1) enzyme activity and HDL cholesterol levels remain stable with age. However, serum total cholesterol and LDL cholesterol decrease significantly in older adults, suggesting age-related metabolic shifts.
Area of Science:
- Biochemistry
- Gerontology
- Cardiovascular Science
Background:
- Paraoxonase1 (PON1) is an HDL-associated enzyme with hydrolytic functions against organophosphate toxins and oxidized phospholipids.
- PON1's activity is linked to preventing organophosphate poisoning and inhibiting atherosclerosis.
- Aging may influence PON1 activity and its role in cardiovascular health.
Purpose of the Study:
- To investigate the impact of aging on serum paraoxonase activity and HDL cholesterol levels.
- To examine age-related changes in lipid profiles, including total cholesterol and LDL cholesterol.
- To assess the relationship between aging, PON1 activity, and antiatherogenic potential.
Main Methods:
- Study included 187 individuals (30-95 years) divided into young, middle-aged, and elderly groups.
- Measured serum paraoxonase activity, HDL cholesterol, total cholesterol, and LDL cholesterol levels.
- Analyzed body mass index and PON1 phenotypes (AA, AB, BB) across age groups.
Main Results:
- Serum total cholesterol and LDL cholesterol significantly decreased with age (P < 0.05).
- Elderly individuals had a significantly lower body mass index than the middle-aged group (P < 0.05).
- Serum paraoxonase activity and HDL cholesterol levels showed no significant changes with age.
Conclusions:
- Aging does not significantly alter serum paraoxonase activity or HDL cholesterol levels.
- Age-related decreases in total and LDL cholesterol were observed.
- PON1 phenotype distribution was consistent across the studied age groups.
Related Concept Videos
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...